Capstone Therapeutics Q2 2025 Results: Gross Margin Jumps to 24.4%, First Acquisition Imminent

Reuters
Aug 15
Capstone <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Gross Margin Jumps to 24.4%, First Acquisition Imminent

Capstone Holding Corp. (NASDAQ: CAPS) has released its second quarter 2025 financial results, reporting a substantial increase in its gross margin, which rose to 24.4% from 21.4% in the same period the previous year. This improvement is attributed to increased sales of owned brands and disciplined cost management. The company is advancing its acquisition of a Carolina-based stone company, expected to close within the next 10 days. This acquisition is anticipated to be immediately accretive to revenue and EBITDA, expanding Capstone's presence in the high-growth Southeast market. Capstone is targeting a $100 million revenue run-rate by the end of 2025 or the first quarter of 2026, with additional acquisitions under review at attractive valuations. The company has secured flexible capital funding through an Equity Line of Credit and a convertible note, ensuring the availability of funds for future acquisitions without relying on high-interest debt. Looking ahead, Capstone expects a rebound in Q3 order volumes as market conditions stabilize, with potential interest rate cuts in late 2025 providing additional demand support. The company continues to focus on product rollouts and expanding into new territories to maintain momentum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1061481) on August 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10